Back to News
Market Impact: 0.3
What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call
Source: marketbeat.com
Healthcare & BiotechProduct LaunchesCorporate EarningsCompany Fundamentals
Viridian Therapeutics reported $24.7 million in net product revenue from Lumvoa during the thyroid eye disease treatment’s first quarter on the market. More than 100 patients had received at least one infusion by Sept. 30.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
VRDN0.60
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales